Xenon Pharmaceuticals 10.5M share Spot Secondary priced at $57.00

By TheFly | March 11, 2026, 6:00 AM

The deal size was increased to $650M in common stock from $500M in common stock. JPMorgan, Jefferies, TD Cowen, Stifel, RBC Capital and William Blair acted as joint book running managers for the offering.

Claim 70% Off TipRanks Premium

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on XENE:

Disclaimer & Disclosure Report an Issue

Mentioned In This Article

XENE

-1.52%

Xenon Pharmaceuticals Inc

Latest News

4 hours	Xenon Pharmaceuticals 10.5M share Spot Secondary priced at $57.00 XENE TipRanks
Mar-10	Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering XENE GlobeNewswire
Mar-10	XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study XENE Zacks
Mar-10	Xenon hits a home run in epilepsy; FDA restarts review of Duchenne cell therapy XENE BioPharma Dive
Mar-09	50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today XENE +49.64% 24/7 Wall St.
Mar-09	Xenon Smashes Its Previous Record High On 'Unprecedented' Results. Is A Buyout Next? XENE +49.64% Investor's Business Daily
Mar-09	Xenon Pharmaceuticals Announces Proposed Public Offering XENE +49.64% GlobeNewswire
Mar-09	Analysts tout market potential of Xenons epilepsy drug on Phase III win XENE +49.64% Clinical Trials Arena
Mar-09	What's Going On With Biohaven Stock On Monday? XENE +49.64% Benzinga
Mar-09	Xenon Pharmaceuticals Rallies After Pivotal Data Shows Major Drop In Monthly Seizures XENE +49.64% Benzinga
Mar-09	Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS) XENE +49.64% GlobeNewswire
Mar-08	Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026 XENE GlobeNewswire
Mar-04	Xenon Pharmaceuticals Stock Sees RS Rating Rise To 77 XENE Investor's Business Daily
Feb-27	Xenon Q4 Loss Wider Than Expected, Pipeline Development in Focus XENE Zacks
Feb-26	Xenon Pharmaceuticals: Q4 Earnings Snapshot XENE Associated Press Finance

Xenon Pharmaceuticals 10.5M share Spot Secondary priced at $57.00

Claim 70% Off TipRanks Premium

Mentioned In This Article

Latest News

Upgrade your FINVIZ experience